Sharon Hashmueli
Clinical trials
Chemomab
Israel
Biography
Dr. Sharon Hashmueli joined ChemomAb in 2016 as head of CMC and regulatory affairs with over 15 years of experience in drug development, and is responsible for the pre-clinical safety evaluations, regulatory affairs, GMP manufacturing and clinical operations. Prior to joining ChemomAb, Dr. Hashmueli worked at cCAM Biotherapeutics (acquired by Merck in 2015) developing a novel immune checkpoint inhibitor for cancer, and beforehand at Protalix Biotherapeutics, where she played a significant role in the development of Elelyso, an FDA approved treatment for Gauche disease (marketed by Pfizer since 2012). Dr. Hashumueli is experienced in regulatory affairs, including strategic planning, CMC, GMP manufacturing and clinical trial applications for biological products. Her experience also includes pre-clinical and clinical research development in Phase I/II and Phase III global clinical trials. Dr. Hashmueli holds a Ph.D in Biotechnology and Food Engineering from the Technion, Israel Institute of Technology.
Research Interest
Clinical trials
